Stem cell-based multi-tissue platforms to model human autoimmune diabetes
Recent advances in reprogramming approaches to create patient-specific induced pluripotent stem cell lines (iPSCs), genome engineering technologies to efficiently modify DNA of hPSCs, and protocols to direct their differentiation into mature cell types have empowered the use of stem cell derivatives to accurately model human disease. While challenges remain before complex interactions occurring in human T1D can be modeled with these derivatives, experiments combining hPSC-derived β cells and immune cells are already providing exciting insight into how these cells interact in the context of T1D, supporting the viability of this approach. Copyright © 2022 The Authors. Published by Elsevier GmbH.. All rights reserved.
|Authors||Leavens KF, Alvarez-Dominguez JR, Vo LT, Russ HA, Parent AV|
|Publication Date||2022 Dec;66:101610|